Allergan’s Commitment to Research and Development Pushes Forward

Allergan’s Commitment to Research and Development Pushes Forward

December 15, 2014
By Carolynn Grimes
The Plastic Surgery Channel

Heading into the New Year, the CEO’s of Allergan and Actavis say there will be virtually no change in Allergan’s commitment to its customers, physicians, and research and development.

 

Both companies are well run businesses that have a strong commitment to innovation and research and development.  Allergan, maker of Botox, recently agreed to be acquired for $66 billion by Actavis, who makes generic and brand-name medicines. Combining Actavis and Allergan will create one of the 10 largest global drug makers, with more than $20 billion expected in revenue next year.

Actavis CEO and President, Brent Saunders, said they would keep spending on R&D, contrasting to Valeant Pharmaceutical’s pledges to reduce research spending by 90% during their hostile takeover attempt earlier this year.  “We were very concerned about what Valeant would have done to Allergan and I think the most dramatic statement was their wanting to reduce our R & D budget by 90%. They would have come in here and basically destroyed everything except very late stage clinical development,” said David Pyott, CEO of Allergan.

Saunders said research and development is the lifeblood of Actavis, which is good news for customers and physicians who were concerned a buyout would mean an end to physician education and customer service.

Continuing a Great Track Record with the Plastic Surgery Community

wp1As the two companies entered into discussions, it became clear Actavis’ values are very similar to those of Allergan. The latter has always had close ties to the entire network of patient care, from supporting medical education to being a strong supporter of the medical societies.

“We have tremendous focus on the customer and not just the customer in the simplest of sense where we call on a doctor’s office and supply them with samples and provide them with information, but much, much broader than that,” said Pyott.

Job Cuts in the Forecast

“Our commitment to our customers and our plastic surgeons will be unwavering,” said Saunders.  “You should notice no change, and hopefully over time a stronger commitment from the combined companies. While both Pyott and Saunders are positive about the acquisition, there will be changes in staff within the two companies.  “While Brent (Saunders) and I are very open with our teams, we tell them, when mergers and acquisitions occur there has to be reductions of duplicate spending,” said Pyott.

 

Click to add a comment

More in

Extreme weight loss creates surge in plastic surgery.

Extreme Weight Loss Creates Surge in Plastic Surgery

Dawn TongishMay 17, 2018
Choosing the right breast implants.

Choosing the Right Breast Implants

Dawn TongishMay 16, 2018
Using platelet-rich plasma to counteract hair loss.

Using Platelet-Rich Plasma To Counteract Hair Loss

Dawn TongishMay 15, 2018
Playing it safe during the big butt boom.

Playing it Safe During the Big Butt Boom

Anne MeyerMay 14, 2018
Surgery to Fix the Belly Button, A Good Idea?

Surgery to Fix the Belly Button, A Good Idea?

Steven CampMay 11, 2018
Improving The Mid Face With Fillers and Fat.

Improving The Mid Face With Fillers and Fat

Dawn TongishMay 9, 2018
Moderation is Good for Your Diet AND Plastic Surgery.

Moderation is Good for Your Diet AND Plastic Surgery

John HammarleyMay 8, 2018
Who to Pick for Vaginal Rejuvenation - Plastic Surgeon or Gynecologist?

Who to Pick for Vaginal Rejuvenation – Plastic Surgeon or Gynecologist?

Patricia McGuire, MDMay 7, 2018
Combined Procedures - How Much is Too Much?

Combined Procedures – How Much is Too Much?

Anne MeyerMay 4, 2018